Hematology
HOPA 2026: Emerging Off-Tumor Toxicities in CAR-T
Dr. Rebecca Gonzales discusses the incidence and mechanisms of novel toxicities due to off-tumor binding that may ...
APRIL 21, 2026
FDA Grants Accelerated Approval to Lynozyfic for Relapsed or Refractory Multiple Myeloma
The FDA granted accelerated approval to Lynozyfic, a BCMA-directed CD3 T-cell engager for adults with relapsed or ...
JULY 8, 2025
FDA Approves Qfitlia for Hemophilia A or B
The FDA approved Qfitlia for adults and children 12 years of age and older with hemophilia A or B, with or without ...
APRIL 7, 2025
Daratumumab Delays Transition From Smoldering to Active Multiple Myeloma
In a phase 3 trial, the anti-38 monoclonal antibody Darzalex substantially delayed or prevented transformation of ...
FEBRUARY 20, 2025
FDA Approves Adcetris With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma
The FDA has approved Adcetris in combination with lenalidomide and a rituximab product for adult patients with ...
FEBRUARY 20, 2025
Supportive Care and Other Tools for Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In patients who received prior chronic lymphocytic leukemia/small lymphocytic lymphoma-directed therapy but require ...
FEBRUARY 10, 2025
FDA Approves Calquence With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
The FDA has granted traditional approval to Calquence with bendamustine and rituximab for adults with previously ...
JANUARY 21, 2025
Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic lymphocytic leukemia is a lymphoproliferative disorder characterized by the accumulation of circulating ...
JANUARY 9, 2025
Steroids Still the Mainstay Treatment for cGVHD
Corticosteroids remain an effective tool for treating chronic graft-versus-host disease, although they are ...
DECEMBER 20, 2024
Harnessing the Potential of CAR T-Cell Therapy for Multiple Myeloma
Multiple myeloma, a blood cancer that develops in plasma cells, can result in low blood counts and weakening of the ...
DECEMBER 20, 2024
FDA Approves Ryoncil for Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients
The FDA approved Ryoncil, an allogeneic bone marrow–derived mesenchymal stromal cell therapy, for ...
DECEMBER 19, 2024
$1 Million Health Plan Savings for Hemophilia Gene Therapy Projected
A gene therapy product approved for adults with hemophilia B may increase initial costs for health plans but can ...
DECEMBER 17, 2024
